ciprofibrate and tyloxapol

ciprofibrate has been researched along with tyloxapol in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Borensztajn, J; Davidson, NO; Fu, T; Mukhopadhyay, D	1

Other Studies

1 other study(ies) available for ciprofibrate and tyloxapol

Article	Year
The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions. The Journal of biological chemistry, 2004, Jul-02, Volume: 279, Issue:27 Topics: Animals; Aorta; Apolipoproteins B; Arteriosclerosis; Blotting, Western; Cholesterol; Clofibric Acid; Cytoplasm; Female; Fibric Acids; Intestinal Mucosa; Lipid Metabolism; Lipoproteins; Lipoproteins, LDL; Liver; Mice; Mice, Inbred C57BL; Mice, Transgenic; Peroxisome Proliferators; Polyethylene Glycols; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; RNA; RNA Editing; RNA, Messenger; Time Factors; Transcription Factors; Triglycerides	2004

Article

Year

The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.

The Journal of biological chemistry, 2004, Jul-02, Volume: 279, Issue:27

Topics: Animals; Aorta; Apolipoproteins B; Arteriosclerosis; Blotting, Western; Cholesterol; Clofibric Acid; Cytoplasm; Female; Fibric Acids; Intestinal Mucosa; Lipid Metabolism; Lipoproteins; Lipoproteins, LDL; Liver; Mice; Mice, Inbred C57BL; Mice, Transgenic; Peroxisome Proliferators; Polyethylene Glycols; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; RNA; RNA Editing; RNA, Messenger; Time Factors; Transcription Factors; Triglycerides

2004